The Germany-based small and medium-sized Company, Molthera GmbH (Witten, Germany) is a Witten-based startup (www.molthera.eu) focused on translational stem cell technology within regenerative dentistry (with special emphasis on regenerative periodontology) with a proven track record in privately and government funded research projects (e.g. Machbarkeitsstudie-Verfahren zur regenerativen Therapie der marginalen Parodontitis unter Nutzung von patienteneigenen adulten Stammzellen, Projekt-Nummer z0606g04, 2007-2013, Projektträger Jülich, Forschungszentrum Jülich GmbH). In addition to early pre-clinical research, Molthera GmbH was involved in a patient observation study (approved by the ethics committee of the Zahnärztekammer Westfalen/Lippe and the University of Münster, AZ 2007-2009-f-s, 17/02/2014) investigating the effects of autologous ADSC-rich palatal tissue transplantation in combination with allogenic bone substitute on mineralization of newly formed bone. Here, the company profits from tight links with three Molthera-associated dental clinics with access to large patient cohorts:

• Praxisteam Hasslinghausen (Prof. Dr. M.A. Vukovic, Univ.-Prof. Dr. Dr. W.-D. Grimm), Sprockhövel, Germany
• NAM-clinics (Prof. Dr. T. Fritsch and partners), Bayerisch-Gmain, Germany
• Dental Implantology Kassel (Prof. Dr. B. Giesenhagen), Kassel, Germany

Furthermore, Molthera GmbH is internationally well connected and has access to cost-efficient animal research facilities in Turkey able to conduct state-of-the-art small- and large animal studies (Cukurova University Adana, Department of Oral and Maxillofacial Surgery, Turkey,Regenerative Medicine Cluster, Advanced Medical and Dental Institute, Universiti Sains Malaysia, Bertam, Penang, Malaysia).

• How do inflammation and infection influence stem cell-mediated regeneration of the bone tissues? Are pro- and anti-inflammatory signals beneficial or harmful to adult stem cells?
• What is the ideal stem cell type for personalized regenerative medicine?
• It is possible to increase the regenerative potential of autologous (belonging to the given patient), tissue-resident stem cells by manipulating the inflammatory balance?
• Can such de-differentiation approach be used within Regenerative Medicine?
• What are the best conditions and methods to cultivate stem cells (3D vs 2D cultures, biomaterials)
• What are the best techniques for vertical and horizontal augmentations of alveolar bone defects using bone substitutes as carrier material for human oral-derived neural crest-related stem cells

<PCT/EP2006/066221>, 07/2009, “A post-natal periodontal-derived neural stem cell”, Molthera GmbH, EP, Patent erteilt, sichert Ergebnisse aus dem Schlüssel-Experiment